Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability

Citations Over TimeTop 23% of 2020 papers

Abstract

Gut microbial communities are capable of enzymatically transforming pharmaceutical compounds into active, inactive, and toxic metabolites, thus potentially affecting the pharmacokinetics and bioavailability of orally administered medications. Our understanding of the impact and clinical relevance of how gut microbial communities can directly and indirectly affect drug metabolism and, ultimately, clinical outcomes, is limited. Interindividual variability of gut microbial composition may partially explain differences observed in drug efficacy and toxicity in certain patient populations. This review provides an overview of how gut microbial communities can potentially contribute to individual drug response. This review focuses on the current landscape of clinical and preclinical research that defines the microbiome contribution on medication response with the goal of improving medication efficacy and decreasing medication toxicity.

Related Papers

• → Vitamins for the Gut Microbiome(2019)113 cited
• → Gut-on-chip for ecological and causal human gut microbiome research(2022)44 cited
• → Microbiome-based stratification to guide dietary interventions to improve human health(2020)35 cited
• → Vegetarian Diets and the Microbiome(2017)6 cited
• → Precision Nutrition from the View of the Gut Microbiome(2022)2 cited